National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

BACKGROUND: Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them. We characterized temporal trends in SGLT2i and GLP‐1RA use by car...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhikari, Rishav, Jha, Kunal, Dardari, Zeina, Heyward, James, Blumenthal, Roger S., Eckel, Robert H., Alexander, G. Caleb, Blaha, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238581/
https://www.ncbi.nlm.nih.gov/pubmed/35475341
http://dx.doi.org/10.1161/JAHA.121.023811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238581/
https://www.ncbi.nlm.nih.gov/pubmed/35475341
http://dx.doi.org/10.1161/JAHA.121.023811

Ejemplares similares